GB0907413D0 - Novel methods - Google Patents

Novel methods

Info

Publication number
GB0907413D0
GB0907413D0 GBGB0907413.9A GB0907413A GB0907413D0 GB 0907413 D0 GB0907413 D0 GB 0907413D0 GB 0907413 A GB0907413 A GB 0907413A GB 0907413 D0 GB0907413 D0 GB 0907413D0
Authority
GB
United Kingdom
Prior art keywords
novel methods
novel
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0907413.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Pharma Callanish Ltd
Original Assignee
Equateq Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Equateq Ltd filed Critical Equateq Ltd
Priority to GBGB0907413.9A priority Critical patent/GB0907413D0/en
Publication of GB0907413D0 publication Critical patent/GB0907413D0/en
Priority to EP10717730.5A priority patent/EP2424520B1/en
Priority to DK10717730.5T priority patent/DK2424520T3/da
Priority to JP2012507810A priority patent/JP5794978B2/ja
Priority to SM20190619T priority patent/SMT201900619T1/it
Priority to NZ596191A priority patent/NZ596191A/en
Priority to US13/318,290 priority patent/US8536223B2/en
Priority to ES10717730T priority patent/ES2745458T3/es
Priority to HRP20191817TT priority patent/HRP20191817T1/hr
Priority to CA2843996A priority patent/CA2843996C/en
Priority to PL10717730T priority patent/PL2424520T3/pl
Priority to PCT/GB2010/000844 priority patent/WO2010125340A1/en
Priority to HK12106556.9A priority patent/HK1165728B/xx
Priority to AU2010243378A priority patent/AU2010243378B2/en
Priority to CN201410058953.3A priority patent/CN103816144A/zh
Priority to CN201080026515.9A priority patent/CN102458391B9/zh
Priority to SI201031942T priority patent/SI2424520T1/sl
Priority to CA2760629A priority patent/CA2760629C/en
Priority to SG2011079431A priority patent/SG175823A1/en
Priority to LT10717730T priority patent/LT2424520T/lt
Priority to EP19180354.3A priority patent/EP3607945A1/en
Priority to KR1020117027648A priority patent/KR101365801B1/ko
Priority to PT107177305T priority patent/PT2424520T/pt
Priority to HUE10717730A priority patent/HUE046581T2/hu
Priority to US13/461,472 priority patent/US8729126B2/en
Priority to JP2013213425A priority patent/JP2014005305A/ja
Priority to US14/203,837 priority patent/US9439850B2/en
Priority to US14/316,375 priority patent/US9216151B2/en
Priority to US14/549,324 priority patent/US9421163B2/en
Priority to JP2015230285A priority patent/JP6254138B2/ja
Priority to US15/213,090 priority patent/US9889106B2/en
Priority to JP2016215916A priority patent/JP2017061495A/ja
Priority to US15/856,254 priority patent/US10328046B2/en
Priority to JP2018105052A priority patent/JP2018150361A/ja
Priority to JP2018105051A priority patent/JP6785027B2/ja
Priority to US16/450,187 priority patent/US10918614B2/en
Priority to CY20191101054T priority patent/CY1122139T1/el
Priority to JP2020092079A priority patent/JP2020147580A/ja
Priority to JP2020092078A priority patent/JP6951506B2/ja
Priority to JP2022032010A priority patent/JP2022071114A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB0907413.9A 2009-04-29 2009-04-29 Novel methods Ceased GB0907413D0 (en)

Priority Applications (40)

Application Number Priority Date Filing Date Title
GBGB0907413.9A GB0907413D0 (en) 2009-04-29 2009-04-29 Novel methods
KR1020117027648A KR101365801B1 (ko) 2009-04-29 2010-04-29 피부 염증 치료를 위한 ｐｕｆａ의 용도
SG2011079431A SG175823A1 (en) 2009-04-29 2010-04-29 Use of pufas for treating skin inflammation
LT10717730T LT2424520T (lt) 2009-04-29 2010-04-29 Pnrr naudojimas odos uždegimo gydymui
JP2012507810A JP5794978B2 (ja) 2009-04-29 2010-04-29 皮膚の炎症を処置するためのｐｕｆａの使用
SM20190619T SMT201900619T1 (it) 2009-04-29 2010-04-29 Uso di pufa per la cura di un'infiammazione cutanea
NZ596191A NZ596191A (en) 2009-04-29 2010-04-29 Use of pufas for treating skin inflammation
US13/318,290 US8536223B2 (en) 2009-04-29 2010-04-29 Use of PUFAs for treating skin inflammation
ES10717730T ES2745458T3 (es) 2009-04-29 2010-04-29 Uso de PUFAS para el tratamiento de la inflamación de la piel
HRP20191817TT HRP20191817T1 (hr) 2009-04-29 2010-04-29 Uporaba pufa za liječenje kožnih upala
CA2843996A CA2843996C (en) 2009-04-29 2010-04-29 Use of pufas for treating skin inflammation
PL10717730T PL2424520T3 (pl) 2009-04-29 2010-04-29 Zastosowanie PUFA do leczenia stanów zapalnych skóry
PCT/GB2010/000844 WO2010125340A1 (en) 2009-04-29 2010-04-29 Use of pufas for treating skin inflammation
HK12106556.9A HK1165728B (en) 2009-04-29 2010-04-29 Use of pufas for treating skin inflammation
AU2010243378A AU2010243378B2 (en) 2009-04-29 2010-04-29 Use of PUFAs for treating skin inflammation
CN201410058953.3A CN103816144A (zh) 2009-04-29 2010-04-29 多不饱和脂肪酸类用于治疗皮肤炎症的用途
DK10717730.5T DK2424520T3 (da) 2009-04-29 2010-04-29 Anvendelse af flerumættede fedtsyrer til behandling af hudinflammation
SI201031942T SI2424520T1 (sl) 2009-04-29 2010-04-29 Uporaba večkrat nenasičenih maščobnih kislin za zdravljenje vnetja kože
CA2760629A CA2760629C (en) 2009-04-29 2010-04-29 Use of pufas for treating skin inflammation
EP10717730.5A EP2424520B1 (en) 2009-04-29 2010-04-29 Use of pufas for treating skin inflammation
EP19180354.3A EP3607945A1 (en) 2009-04-29 2010-04-29 Use of pufas for treating skin inflammation
CN201080026515.9A CN102458391B9 (zh) 2009-04-29 2010-04-29 多不饱和脂肪酸类用于治疗皮肤炎症的用途
HUE10717730A HUE046581T2 (hu) 2009-04-29 2010-04-29 PUFA-k alkalmazása bõrgyulladás kezelésére
PT107177305T PT2424520T (pt) 2009-04-29 2010-04-29 Utilização de pufas para tratar inflamação da pele
US13/461,472 US8729126B2 (en) 2009-04-29 2012-05-01 Use of pufas for treating skin inflammation
JP2013213425A JP2014005305A (ja) 2009-04-29 2013-10-11 皮膚の炎症を処置するためのｐｕｆａの使用
US14/203,837 US9439850B2 (en) 2009-04-29 2014-03-11 Use of pufas for treating skin inflammation
US14/316,375 US9216151B2 (en) 2009-04-29 2014-06-26 Use of PUFAS for treating skin inflammation
US14/549,324 US9421163B2 (en) 2009-04-29 2014-11-20 Topical compositions comprising polyunsaturated fatty acids
JP2015230285A JP6254138B2 (ja) 2009-04-29 2015-11-26 皮膚の炎症を処置するためのｐｕｆａの使用
US15/213,090 US9889106B2 (en) 2009-04-29 2016-07-18 Topical compositions comprising polyunsaturated fatty acids
JP2016215916A JP2017061495A (ja) 2009-04-29 2016-11-04 皮膚の炎症を処置するためのｐｕｆａの使用
US15/856,254 US10328046B2 (en) 2009-04-29 2017-12-28 Topical compositions comprising polyunsaturated fatty acids
JP2018105051A JP6785027B2 (ja) 2009-04-29 2018-05-31 皮膚の炎症を処置するためのｐｕｆａの使用
JP2018105052A JP2018150361A (ja) 2009-04-29 2018-05-31 皮膚の炎症を処置するためのｐｕｆａの使用
US16/450,187 US10918614B2 (en) 2009-04-29 2019-06-24 Topical compositions comprising polyunsaturated fatty acids
CY20191101054T CY1122139T1 (el) 2009-04-29 2019-10-08 Χρηση pufas για θεραπεια δερματικης φλεγμονης
JP2020092079A JP2020147580A (ja) 2009-04-29 2020-05-27 皮膚の炎症を処置するためのｐｕｆａの使用
JP2020092078A JP6951506B2 (ja) 2009-04-29 2020-05-27 皮膚の炎症を処置するためのｐｕｆａの使用
JP2022032010A JP2022071114A (ja) 2009-04-29 2022-03-02 皮膚の炎症を処置するためのｐｕｆａの使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0907413.9A GB0907413D0 (en) 2009-04-29 2009-04-29 Novel methods

Publications (1)

Publication Number Publication Date
GB0907413D0 true GB0907413D0 (en) 2009-06-10

Family

ID=40792027

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0907413.9A Ceased GB0907413D0 (en) 2009-04-29 2009-04-29 Novel methods

Country Status (21)

Country Link
US (8) US8536223B2 (el)
EP (2) EP3607945A1 (el)
JP (9) JP5794978B2 (el)
KR (1) KR101365801B1 (el)
CN (2) CN102458391B9 (el)
AU (1) AU2010243378B2 (el)
CA (2) CA2843996C (el)
CY (1) CY1122139T1 (el)
DK (1) DK2424520T3 (el)
ES (1) ES2745458T3 (el)
GB (1) GB0907413D0 (el)
HR (1) HRP20191817T1 (el)
HU (1) HUE046581T2 (el)
LT (1) LT2424520T (el)
NZ (1) NZ596191A (el)
PL (1) PL2424520T3 (el)
PT (1) PT2424520T (el)
SG (1) SG175823A1 (el)
SI (1) SI2424520T1 (el)
SM (1) SMT201900619T1 (el)
WO (1) WO2010125340A1 (el)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
EP2708230B1 (en) * 2011-05-12 2024-10-02 Nissui Corporation Composition for external skin use for inflammatory diseases
US8936803B2 (en) * 2011-10-19 2015-01-20 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof
US9855236B2 (en) * 2011-10-19 2018-01-02 Ds Biopharma Limited Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
US20120264705A1 (en) * 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
WO2014022816A2 (en) * 2012-08-03 2014-02-06 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hetre and methods of treating or preventing arthritis using same
GB201221329D0 (en) 2012-11-27 2013-01-09 Avexxin As Dermatitis treatment
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
EP3878835A1 (en) 2013-11-15 2021-09-15 DS Biopharma Limited Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids
LT3077489T (lt) 2013-12-04 2021-07-26 Nippon Suisan Kaisha, Ltd. Mikrobinis aliejus, kurio sudėtyje yra dihomo-gama-linoleno rūgštis, ir mikrobinė biomasė, kurios sudėtyje yra dihomo-gama-linoleno rūgštis
CN106163511A (zh) * 2014-01-24 2016-11-23 国立大学法人京都大学 含有稀有脂肪酸的抗炎剂
MA52644A (fr) * 2014-06-04 2021-03-24 Ds Biopharma Ltd Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
MA47141A (fr) 2015-05-13 2019-11-06 Ds Biopharma Ltd Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation
US20170020836A1 (en) 2015-07-21 2017-01-26 Dignity Sciences Limited Compositions Comprising 15-HEPE and Methods of Treating or Preventing Cancer and Neurologic Disease
BR122023026625A2 (pt) 2015-12-18 2024-01-16 Afimmune Limited Uso do ácido 15-hidroxieicosapentaenoico ou derivados farmaceuticamente aceitáveis do mesmo
TWI726027B (zh) * 2015-12-28 2021-05-01 日商大塚製藥股份有限公司 軟膏
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
EP3515422A1 (en) 2016-09-21 2019-07-31 Avexxin AS Pharmaceutical composition
CN110302193B (zh) * 2019-08-14 2022-02-18 中南大学湘雅三医院 一种纳米酸化脂肪酸酯复合物在制备治疗面部毛囊虫皮炎药物中的应用
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
KR102867098B1 (ko) * 2024-12-02 2025-10-02 한국콜마주식회사 아마씨오일 유래 지방산 유도체

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5264452A (en) 1975-11-18 1977-05-27 Nippon Suisan Kaisha Ltd Method of producing processed fish meat
JPS5820575B2 (ja) 1975-11-27 1983-04-23 日本水産株式会社 スイサンカコウヒンノセイゾウホウ
US4273763A (en) 1978-01-23 1981-06-16 Efamol Limited Pharmaceutical and dietary compositions
IE47777B1 (en) 1978-01-23 1984-06-13 Efamol Ltd Pharmaceutical and dietary composition comprising gamma-linolenic acids
US4444755A (en) 1978-01-23 1984-04-24 Efamol Limited Treatment for skin disorders
DE2967049D1 (en) 1978-04-11 1984-07-19 Efamol Ltd Pharmaceutical and dietary composition comprising gamma-linolenic acids
IE49783B1 (en) 1979-05-18 1985-12-11 Efamol Ltd Pharmaceutical and dietary composition comprising epsilon-linolenic acids
IE51145B1 (en) 1980-03-07 1986-10-15 Efamol Ltd Pharmaceutical and dietary compositions
IE53332B1 (en) 1980-03-14 1988-10-26 Efamol Ltd Pharmaceutical compositions
US4386072A (en) 1981-06-26 1983-05-31 Horrobin David F Treatment of disorders of inflammation and immunity and disorders associated with smooth muscle spasm and compositions therefor
US5324748A (en) 1981-07-14 1994-06-28 Efamol Limited Method for enhancement of 1-series PG production
US5145686A (en) 1982-02-03 1992-09-08 Efamol Limited Topical pharmaceutical compositions
AU556817B2 (en) 1982-02-03 1986-11-20 Efamol Limited Topical application of a lithium salt and dihomo-alpha- linolenic acid
DE3366838D1 (en) 1982-03-01 1986-11-20 Efamol Ltd Pharmaceutical composition
ATE22532T1 (de) 1982-03-01 1986-10-15 Efamol Ltd Pharmazeutische zusammensetzung.
ATE19855T1 (de) 1982-03-01 1986-06-15 Efamol Ltd Pharmazeutische und diaetetische zusammensetzung.
ATE22533T1 (de) 1982-04-29 1986-10-15 Efamol Ltd Pharmazeutische zusammensetzung.
GB8302708D0 (en) 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
GB8319073D0 (en) 1983-07-14 1983-08-17 Efamol Ltd Fatty acid compositions
GB8326130D0 (en) * 1983-09-29 1983-11-02 Efamol Ltd Topical preparations containing tars and fatty acids
GB8420771D0 (en) * 1984-08-15 1984-09-19 Efamol Ltd Treatment of skin disorders
GB8425006D0 (en) 1984-10-03 1984-11-07 Efamol Ltd Composition of copper/fatty acids
CH663951A5 (fr) 1984-10-10 1988-01-29 Nestle Sa Procede d'enrichissement selectif en acides gras polyinsatures d'un melange contenant des acides gras fractions enrichies obtenues et compositions les contenant.
GB8506027D0 (en) 1985-03-08 1985-04-11 Efamol Ltd Pharmaceutical & dietary compositions
GB8522670D0 (en) 1985-09-13 1985-10-16 Efamol Ltd Drug treatments
GB8524275D0 (en) 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
CH669208A5 (fr) 1986-12-17 1989-02-28 Nestle Sa Procede de fractionnement en continu d'un melange d'acides gras.
US5198468A (en) 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
EP0309086A1 (en) 1987-09-07 1989-03-29 Efamol Holdings Plc Treatment of male pattern baldness and of unwanted hair growth
GB8729153D0 (en) 1987-12-14 1988-01-27 Efamol Ltd Fatty acid compositions
WO1990014824A1 (en) 1988-01-14 1990-12-13 Anders Frithz Use of essential fatty acids for the preparation of a drug for the treatment of eczema
GB8806737D0 (en) 1988-03-22 1988-04-20 Efamol Holdings Therapeutic composition & method
US6140304A (en) 1988-09-28 2000-10-31 Eicotech Corporation Method of and nutritional and pharmaceutical compositions for reduction of hyperinsulinemia
GB8916734D0 (en) 1989-07-21 1989-09-06 Efamol Holdings Pharmaceutical and dietary uses of fatty acids
GB8918294D0 (en) 1989-08-10 1989-09-20 Efamol Holdings Pharmaceutical compositions
GB8920228D0 (en) * 1989-09-07 1989-10-18 Efamol Holdings Fatty acid therapy
JPH04290820A (ja) * 1991-03-18 1992-10-15 Idemitsu Petrochem Co Ltd 皮膚病犬の治療方法とその薬剤
GB9111900D0 (en) 1991-06-03 1991-07-24 Efamol Holdings Fatty acid compositions
GB9112052D0 (en) 1991-06-05 1991-07-24 Efamol Holdings Fatty acid treatment
JP3354581B2 (ja) 1991-09-30 2002-12-09 サントリー株式会社 ジホモ−γ−リノレン酸及びこれを含有する脂質の製造方法
GB9211229D0 (en) * 1992-05-27 1992-07-08 Efamol Holdings Fatty acid treatment
US5888541A (en) 1992-08-21 1999-03-30 Scotia Holdings Plc Fatty acid treatment
GB9217780D0 (en) 1992-08-21 1992-10-07 Efamol Holdings Fatty acid treatment
FI101039B (fi) 1992-10-09 1998-04-15 Eeva Kristoffersson Menetelmä lääkepellettien valmistamiseksi
DE4238869C2 (de) 1992-11-18 1994-09-08 Wogepharm Gmbh Mittel zur Behandlung des atopischen Ekzems und anderer entzündlicher Hautkrankheiten
GB9301446D0 (en) 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
AU683027B2 (en) 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
CA2119000A1 (en) 1993-03-19 1994-09-20 David Frederick Horrobin Formulation for use in smokers
GB9403855D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
AU711482B2 (en) 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications
US5709855A (en) * 1995-09-22 1998-01-20 Bockow; Barry I. Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
GB9621373D0 (en) 1996-10-14 1996-12-04 Scotia Holdings Plc Fatty acid treatment
GB9710351D0 (en) 1997-05-20 1997-07-16 Scotia Holdings Plc Glucosamine fatty acids
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
CA2332272A1 (en) 1998-05-15 1999-11-25 University Of Vermont Novel analogs of 16-hydroxyeicosatetraenoic acid
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
GB9916536D0 (en) 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
PL356093A1 (en) 1999-11-09 2004-06-14 Alcon Inc. Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders
ATE504557T1 (de) 2000-02-16 2011-04-15 Brigham & Womens Hospital Aspirin-ausgelöste lipidmediatoren
CA2304906A1 (en) 2000-04-07 2001-10-07 1411198 Ontario Limited 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
GB0016452D0 (en) 2000-07-04 2000-08-23 Kilgowan Limited Vitamin K and essential fatty acids
JP2002047176A (ja) 2000-08-04 2002-02-12 Idemitsu Technofine Co Ltd ＩｇＥ産生抑制剤
US20020188024A1 (en) 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
DE10121252A1 (de) 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
US6462084B1 (en) 2001-05-14 2002-10-08 Brookhaven Science Associates, Llc Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
PT1390025E (pt) 2001-05-30 2005-08-31 Laxdale Ltd Utilizacao de coenzima q (ubiquinona) e acido eicosapentaenoico (epa) para o tratamento de linfoma nao de hodgkin e de distubios psiquiatricos ou neurologicos
US20030073930A1 (en) 2001-10-17 2003-04-17 Morrissey Gerald R. Methods and device for preventing or healing injured nipples or areolas in mammalian females or for obtaining samples from nipples in mammalian females
US20030105445A1 (en) 2001-11-30 2003-06-05 Kimberly-Clark Worldwide, Inc. Breast pad assembly containing a skin benefit ingredient
US20030194446A1 (en) 2002-04-10 2003-10-16 Akes Lindy K. Zinc oxide compositions for dermatheraputics
WO2004026259A2 (en) 2002-09-20 2004-04-01 Griscom Bettle, Iii Transdermal compositions
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
GB2409644B (en) 2003-12-31 2005-12-21 Igennus Ltd Formulation comprising eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof
DK1756280T3 (en) 2004-04-22 2015-02-02 Commw Scient Ind Res Org SYNTHESIS OF CHAIN, polyunsaturated fatty acids BY RECOMBINANT CELLS
US20050239889A1 (en) 2004-04-26 2005-10-27 Jean Gosselin In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
US20060009522A1 (en) 2004-07-01 2006-01-12 Reza Dana Compositions and methods for treating eye disorders and conditions
US7666447B2 (en) 2004-10-08 2010-02-23 Pharmanutrients Compositions including Krill extracts and conjugated linoleic acid and methods of using same
US7893106B2 (en) 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
JP2006306812A (ja) 2005-04-28 2006-11-09 Suntory Ltd 好酸球浸潤抑制剤
JP5546087B2 (ja) * 2005-02-14 2014-07-09 サントリーホールディングス株式会社 皮膚疾患経口治療または予防剤
WO2006085687A1 (ja) * 2005-02-14 2006-08-17 Suntory Limited ジホモ−γ−リノレン酸（ＤＧＬＡ）を有効成分として含んで成る組成物
TW200711649A (en) 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
WO2007079224A2 (en) 2005-12-30 2007-07-12 Wei-Wu He Sirna compositions promoting scar-free wound healing of skin and methods for wound treatment
CA2649337C (en) 2006-04-13 2014-11-18 Nippon Suisan Kaisha, Ltd. Process for preparing concentrated polyunsaturated fatty acid oil
GB0611240D0 (en) 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production
CA2662987A1 (en) 2006-08-08 2008-02-21 Tethys Bioscience, Inc. Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
FR2906716B1 (fr) 2006-10-06 2013-05-17 Clarins Lab Utilisation d'une composition cosmetique pour le soin des peaux grasses.
US20080125487A1 (en) 2006-11-17 2008-05-29 Tapas Das Elongase gene and uses thereof
WO2008070129A2 (en) * 2006-12-05 2008-06-12 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
JP5101894B2 (ja) 2007-01-15 2012-12-19 サントリーホールディングス株式会社 高度不飽和脂肪酸及びこれを含有する脂質の製造方法
US20080213357A1 (en) 2007-02-12 2008-09-04 Andrew Bruce Hebard Plant Derived Lipid Useful for Nutraceutical and Cosemeceutical Applications
ITMI20070555A1 (it) 2007-03-21 2007-06-20 Giuliani Spa Composizione provvista di attivita' di inibizione sulla 5 alfa-reduttasi
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
WO2009130291A2 (de) 2008-04-25 2009-10-29 Basf Plant Science Gmbh Pflanzensamenöl
EP2159732A1 (en) 2008-08-21 2010-03-03 Thomson Licensing Method and device for code obfuscation
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
GB0907601D0 (en) 2009-05-01 2009-06-10 Equateq Ltd Novel methods
US8399226B2 (en) 2009-06-16 2013-03-19 E I Du Pont De Nemours And Company High eicosapentaenoic acid oils from improved optimized strains of Yarrowia lipolytica
US8188335B2 (en) 2009-07-17 2012-05-29 Abbott Laboratories Δ9-elongase for production of polyunsaturated fatty acid-enriched oils
CN103384521A (zh) 2010-12-21 2013-11-06 雀巢产品技术援助有限公司 用于预防和治疗骨关节炎的方法和组合物
WO2012135032A2 (en) 2011-03-25 2012-10-04 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
EP2508180A1 (en) 2011-04-04 2012-10-10 Nestec S.A. Sn-1(3) Monoacylglycerides and lipid absorption
US8936803B2 (en) 2011-10-19 2015-01-20 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
CN104114709A (zh) 2011-11-29 2014-10-22 尊贵科学有限公司 包含20-碳脂肪酸的组合物及其制备和使用方法
RS57777B1 (sr) 2012-01-06 2018-12-31 Omthera Pharmaceuticals Inc Dpa-obogaćene kompozicije omega-3 polinezasićenih masnih kiselina u obliku slobodne kiseline
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
US20150079164A1 (en) 2012-04-04 2015-03-19 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
EP4205546A1 (en) 2012-05-10 2023-07-05 Solutex NA LLC Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
WO2014022816A2 (en) 2012-08-03 2014-02-06 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hetre and methods of treating or preventing arthritis using same
US8729726B2 (en) * 2012-10-12 2014-05-20 M. Hassan Hassan Petroleum-alternative power plant
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MA52644A (fr) 2014-06-04 2021-03-24 Ds Biopharma Ltd Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation
US20170196825A1 (en) 2016-01-07 2017-07-13 Dignity Sciences Limited Pharmaceutical compositions comprising dgla and use of same

Also Published As

Publication number Publication date
US20160324819A1 (en) 2016-11-10
US20120213824A1 (en) 2012-08-23
ES2745458T3 (es) 2020-03-02
JP2020147580A (ja) 2020-09-17
SI2424520T1 (sl) 2019-11-29
US9439850B2 (en) 2016-09-13
US20140309304A1 (en) 2014-10-16
PT2424520T (pt) 2019-10-30
CN102458391B (zh) 2014-06-04
US10918614B2 (en) 2021-02-16
US8536223B2 (en) 2013-09-17
JP2017061495A (ja) 2017-03-30
JP2022071114A (ja) 2022-05-13
JP2014005305A (ja) 2014-01-16
EP3607945A1 (en) 2020-02-12
AU2010243378B2 (en) 2014-03-27
US9421163B2 (en) 2016-08-23
JP6785027B2 (ja) 2020-11-18
JP6254138B2 (ja) 2017-12-27
KR20120013394A (ko) 2012-02-14
CA2760629A1 (en) 2010-11-04
LT2424520T (lt) 2019-10-25
SG175823A1 (en) 2011-12-29
JP2018145195A (ja) 2018-09-20
AU2010243378A1 (en) 2011-11-24
PL2424520T3 (pl) 2020-02-28
KR101365801B1 (ko) 2014-02-20
SMT201900619T1 (it) 2020-01-14
HRP20191817T1 (hr) 2019-12-27
EP2424520B1 (en) 2019-07-24
CN103816144A (zh) 2014-05-28
US20150164842A1 (en) 2015-06-18
CN102458391B9 (zh) 2020-09-29
US9889106B2 (en) 2018-02-13
DK2424520T3 (da) 2019-09-30
JP2012525363A (ja) 2012-10-22
CA2843996C (en) 2022-07-12
JP2018150361A (ja) 2018-09-27
JP6951506B2 (ja) 2021-10-20
WO2010125340A1 (en) 2010-11-04
CY1122139T1 (el) 2020-11-25
US20120142773A1 (en) 2012-06-07
HK1165728A1 (en) 2012-10-12
JP5794978B2 (ja) 2015-10-14
CA2760629C (en) 2015-03-24
US20140194399A1 (en) 2014-07-10
NZ596191A (en) 2014-07-25
US20180116991A1 (en) 2018-05-03
US8729126B2 (en) 2014-05-20
US10328046B2 (en) 2019-06-25
CN102458391A (zh) 2012-05-16
HUE046581T2 (hu) 2020-03-30
JP2020143138A (ja) 2020-09-10
CA2843996A1 (en) 2010-11-04
US20190314317A1 (en) 2019-10-17
EP2424520A1 (en) 2012-03-07
US9216151B2 (en) 2015-12-22
JP2016029115A (ja) 2016-03-03

Similar Documents

Publication Publication Date Title
DK3023438T3 (en) Anti-gitr-antistoffer
DK2457337T3 (en) Specialtilpasset impuls-burst
DK2442650T4 (en) Sublingualt apomorfin
GB0907413D0 (en) Novel methods
EP2462514A4 (en) GREEN BOOKS
GB0909645D0 (en) Methods
EP2515891A4 (en) 3-keto-N-propargyl-1-aminoindan
ZA201109437B (en) Novel azabicyclohexanes
GB0907350D0 (en) Methods
ZA201105535B (en) Novel tricyanoborates
EP2519921A4 (en) CALL TRACING
GB0901001D0 (en) Methods
DK2464943T3 (en) Systemintegration
GB0912685D0 (en) Methods
GB0900555D0 (en) New methods
GB0907601D0 (en) Novel methods
GB0912159D0 (en) Methods
GB0903026D0 (en) Novel method
GB0900568D0 (en) Poymerisation
GB0900319D0 (en) Hydrocharger
EP2510125A4 (en) HYPER PRIMER
AU4926P (en) Bonscalib Scaevola aemula
AU4924P (en) Bonscablue Scaevola aemula
AU4240P (en) Tuckerbox xTriticosecale
GB0904209D0 (en) Methods

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)